FGEN - FibroGen, Inc.
| Previous close | 45.58 |
| Open | 45.22 |
| Bid | 44.83 x 1400 |
| Ask | 44.86 x 800 |
| Day's range | 44.62 - 45.60 |
| 52-week range | 32.33 - 61.23 |
| Volume | 131,508 |
| Avg. volume | 606,395 |
| Market cap | 3.908B |
| Beta (5Y monthly) | 1.96 |
| PE ratio (TTM) | 96.54 |
| EPS (TTM) | 0.46 |
| Earnings date | 01 Mar 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 65.17 |
- Zacks
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
- Simply Wall St.
FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Zacks
Are Options Traders Betting on a Big Move in FibroGen (FGEN) Stock?
Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately.
- Simply Wall St.
Is FibroGen's (NASDAQ:FGEN) 136% Share Price Increase Well Justified?
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- Zacks
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 3.39% and 8.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
FibroGen (FGEN) Soars: Stock Adds 9.6% in Session
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
- Zacks
Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss
Mallinckrodt (MNK) misses on sales but beats on earnings in the third quarter of 2019.
- Zacks
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales
Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.
- Zacks
Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%
Karyopharm (KPTI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks
Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance
Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.
- Zacks
Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y
Endo (ENDP) reports better-than-expected results for the third quarter as Xiaflex delivers a strong performance.
- Zacks
5 Stocks With High Net Income Ratio to Grab Now
Investors always have a keen eye for companies having a high level of profitability regardless of the market condition.
- Simply Wall St.
Does Market Volatility Impact FibroGen, Inc.'s (NASDAQ:FGEN) Share Price?
If you own shares in FibroGen, Inc. (NASDAQ:FGEN) then it's worth thinking about how it contributes to the volatility...
- Zacks
Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock
Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock
- Zacks
5 Stocks With High Net Income Ratio to Scoop Up
Profitability analysis is one of the best ways to evaluate the prospects of a company. It is used in detecting a profitable company over a loss-making one.
- Zacks
FibroGen Enters Oversold Territory
FibroGen, Inc. (FGEN) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Zacks
Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2%
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
- Zacks
Tyme Initiates Pivotal Stage of Pancreatic Cancer Study
Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.
- Zacks
BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors
BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.
- Zacks
Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%
Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- Zacks
Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
